Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126581594 | 12658159 | 4 | F | 20160729 | 20160811 | 20160817 | 20160823 | EXP | ZA-CIPLA LTD.-2016ZA17150 | CIPLA | 0.00 | Y | 0.00000 | 20160823 | CN | ZA | ZA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126581594 | 12658159 | 1 | I | DEPRAMIL | CITALOPRAM HYDROBROMIDE | 1 | Oral | 20 MG, DAILY | U | U | UNKNOWN | 0 | 20 | MG | TABLET | ||||
| 126581594 | 12658159 | 2 | PS | RISPERIDONE. | RISPERIDONE | 1 | Oral | UNK, 1 DAILY | U | U | 77543 | ||||||||
| 126581594 | 12658159 | 3 | C | OXAZEPAM. | OXAZEPAM | 1 | Oral | UNK, 1 DAILY | U | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126581594 | 12658159 | 1 | Anxiety |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126581594 | 12658159 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126581594 | 12658159 | Burning sensation | |
| 126581594 | 12658159 | Condition aggravated | |
| 126581594 | 12658159 | Drug interaction | |
| 126581594 | 12658159 | Paraesthesia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126581594 | 12658159 | 1 | 20160728 | 0 |